Clinical trial
An Open Label Phase 1b Study to Characterise the Pharmacokinetic/Pharmacodynamic Relationship and Safety of MMV367 in Healthy Adult Participants Experimentally Infected With Blood Stage Plasmodium Falciparum
NCT05979207 is registered in ClinicalTrials.gov with Medicines for Malaria Venture as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label Phase 1b Study to Characterise the Pharmacokinetic/Pharmacodynamic Relationship and Safety of MMV367 in Healthy Adult Participants Experimentally Infected With Blood Stage Plasmodium Falciparum
- Lead sponsor
- Medicines for Malaria Venture
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 1, 2023
- Completion date
- October 30, 2023
- Enrollment
- 12 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
anti-infective agents, antimalarials, infections, inflammation, malaria, malaria,falciparum, parasitemia, parasitic diseases, pathologic processes, protozoan infections, systemic inflammatory response syndrome, vector borne diseases